Figure 1. Transfer of Omalizumab and Peanut protein across the
placental barrier.
(A) In the human placental ex vivo model sample in-flow (artery)
and out-flow (vein) are recorded to and from the placental tissue. (B)
Omalizumab and (C) peanut extract transfer kinetics as percent change
from maternal artery to fetal vein detected via ELISA.
Figure 2 . Placental peanut allergen transfer in the
context of plasma from allergic individual and omalizumab . (A) Ara h 2
concentrations (ng/mL) in fetal vein and artery samples were determined
by ELISA in PE alone (dashed line, 1.03 ng/mL) and PE/PA compared to
PE/PA/Oma experiments. (B) Basophil activation tests were conducted by
flow cytometry to assess the functionality of transferred allergen.
Activation levels are expressed as %CD63+ basophils
in PE, PE/PA and PE/PA/Oma experiments.